Green Thumb (OTCQX: GTBIF) grows Q1 2026 revenue to $300.2M and boosts buybacks
Rhea-AI Filing Summary
Green Thumb Industries Inc. reported first quarter 2026 revenue of $300.2 million, up 7.4% from a year earlier, with GAAP net income of $15.4 million or $0.07 per basic and diluted share. Gross margin was 47.9% and Normalized EBITDA reached $93.5 million, or 31.2% of revenue.
Growth was driven by retail sales, including the September 2025 launch of adult-use sales in Minnesota and strength in Connecticut and Florida, partially offset by price compression and competition. Cash flow from operations was $76.0 million and cash totaled $344.5 million. The company repurchased about 6.0 million shares in the quarter and 29.0 million overall since September 2023, and highlighted benefits from U.S. federal rescheduling of medical cannabis and a conditional Texas license award.
Positive
- Profitability and cash generation improved: GAAP net income rose to $15.4 million with EPS of $0.07, Normalized EBITDA reached $93.5 million (31.2% margin), and cash flow from operations was $76.0 million.
- Capital returns and strategic positioning: The company has repurchased about 29.0 million shares for approximately $200.0 million since September 2023 and is preparing for U.S. federal medical cannabis rescheduling and a conditional Texas license.
Negative
- None.
Insights
Strong Q1 growth, solid cash flow and sizable buybacks support Green Thumb’s cannabis strategy.
Green Thumb Industries generated Q1 2026 revenue of $300.2 million, up 7.4% year over year, with GAAP net income of $15.4 million and EPS of $0.07. Normalized EBITDA was $93.5 million, or 31.2% of revenue, showing healthy underlying profitability despite price compression.
Operations produced cash flow from operations of $76.0 million, and cash reached $344.5 million against total debt of $289.9 million. Management is actively returning capital, repurchasing about 6.0 million shares in the quarter and roughly 29.0 million shares for about $200.0 million since September 2023.
Strategically, the company noted federal rescheduling of medical cannabis to Schedule III and related Section 280E tax relief for its medical business, plus a conditional Texas Compassionate Use Program license and DEA registration applications. These items signal potential long-term benefits, while future filings will show how they translate into revenue and margin trends.
8-K Event Classification
Key Figures
Key Terms
Normalized EBITDA financial
Section 280E financial
Schedule III regulatory
forward-looking statements regulatory
Offering Details
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Regulation FD Disclosure
On May 6, 2026, Green Thumb Industries Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is attached as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
|
|
|
99.1 |
|
Press release dated May 6, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the inline XRBL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
GREEN THUMB INDUSTRIES INC. |
|
|
|
|
Date: |
May 6, 2026 |
By: |
/s/ Mathew Faulkner |
|
|
|
Mathew Faulkner |
Exhibit 99.1
Green Thumb Industries Reports First Quarter 2026 Results
CHICAGO and VANCOUVER, British Columbia, May 6, 2026 (GLOBE NEWSWIRE) – Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today reported its financial results for the first quarter ended March 31, 2026. Financial results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”), and all currency is in U.S. dollars.
Highlights for the first quarter ended March 31, 2026:
Subsequent to Quarter End
See definitions and reconciliation of non-GAAP measures elsewhere in this release.
Management Commentary
“The Green Thumb team delivered a strong start to 2026, with first quarter revenue of $300 million, Normalized EBITDA of $94 million and cash flow from operations of $76 million,” said Green Thumb Founder, Chairman, and Chief Executive Officer Ben Kovler. “The recent federal action to reschedule medical cannabis from Schedule I to Schedule III is a historic step forward for our business, for investors, and for the country. Our conviction in Green Thumb remains as strong as ever, as reflected in the approximately 13.4 million shares we have repurchased so far this year. As the landscape around us continues to evolve, our team remains focused on disciplined execution and building for the future.”
Green Thumb President Anthony Georgiadis added, “With medical cannabis now rescheduled, the resulting Section 280E relief for the medical portion of our business creates meaningful flexibility to reinvest in our operations, our people, and the communities we serve. Consumer demand for THC continues to rise, and rescheduling helps create a more practical framework for companies like Green Thumb to meet that demand responsibly while continuing to grow and scale our business. Our team is ready for this next chapter in cannabis, and we look forward to continuing to serve patients and consumers while keeping momentum at the federal level toward broader reform and legalization.”
Green Thumb Industries Inc.
Page 2 of 7
First Quarter 2026 Financial Overview
Total revenue for the first quarter was $300.2 million, up 7.4% from the prior year period. Overall retail revenue increased 4.7% versus the first quarter of 2025. Revenue growth in the first quarter was driven by retail sales in Minnesota, reflecting our launch of adult-use sales in the state on September 17, 2025, as well as continued growth in existing markets, particularly Connecticut and Florida, partially offset by price compression and increased competition. First quarter 2026 same store comparable sales (stores open at least 12 months) decreased 0.5% versus the prior year on a base of 100 stores.
Consumer Packaged Goods' gross revenue for the first quarter decreased by 1.6% versus the prior year period, primarily due to price compression and increased competition, partially offset by the launch of adult-use sales in Minnesota.
Gross profit for the first quarter 2026 was $143.6 million or 47.9% of revenue, compared to $143.3 million or 51.3% of revenue over the prior year period. The decline in gross margin was primarily driven by brand license fees incurred in the current period and price compression as discussed above.
Total selling, general and administrative expenses for the first quarter 2026 were $102.9 million or 34.3% of revenue, compared to $100.8 million or 36.1% of revenue for the first quarter 2025. The increase in selling, general, and administrative expenses was primarily attributable to increased compensation costs during the year.
Total other income (expense) for the first quarter 2026 was $22.4 million versus ($2.8) million for the comparable period in the prior year. Excluding a one-time arbitration settlement of $17 million and income associated with the Company's related party equity method investment of $6.5 million, total other income (expense) would have been ($1.1) million.
Net income attributable to the Company for the first quarter 2026 was $15.4 million or $0.07 per basic and diluted share, up from net income of $8.3 million, or $0.04 per basic and diluted share, in the prior year period. The increase in net income attributable to the Company was primarily due to the one-time arbitration settlement and the Company's related party equity method investment, as discussed above.
In the first quarter 2026, EBITDA was $73.1 million or 24.4% of revenue, versus $71.9 million or 25.7% of revenue for the comparable prior year period. Normalized EBITDA, which excludes licensing fees paid, non-cash stock-based compensation of $10.5 million and other non-operating adjustments of $0.9 million, was $93.5 million or 31.2% of revenue, up from $85.2 million or 30.5% of revenue for the first quarter 2025.
For additional information on the non-GAAP financial measures discussed above, see “Non-GAAP Financial Information” below.
Balance Sheet and Liquidity
As of March 31, 2026, current assets were $673.9 million, including cash and cash equivalents of $344.5 million. Total debt outstanding was $289.9 million, which includes $188.8 million of senior debt.
Total basic and diluted weighted average shares outstanding for the three months ended March 31, 2026, were 230.6 million shares and 231.8 million shares, respectively.
Capital Allocation
During the first quarter 2026, the Company repurchased approximately 6.05 million Subordinate Voting Shares for a total amount of approximately $33.3 million, at an average price of $5.51 per share.
Subsequent to quarter end, the Company repurchased approximately 7.4 million additional Subordinate Voting Shares, bringing total repurchases since initiating its share repurchase program to approximately 29.0 million shares for approximately $200.0 million.
Green Thumb Industries Inc.
Page 3 of 7
Non-GAAP Financial Information
This press release includes certain non-GAAP financial measures as defined by the U.S. Securities and Exchange Commission. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles (“GAAP”) are included in the financial schedules attached to this press release. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with GAAP.
Definitions
EBITDA: Earnings before interest, taxes, other income or expense and depreciation and amortization.
Adjusted EBITDA: Earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash stock-based compensation, one-time transaction related expenses, or other non-operating costs.
Normalized EBITDA: Adjusted EBITDA plus brand license fees.
Green Thumb Industries Inc.
Page 4 of 7
About Green Thumb Industries
Green Thumb Industries Inc. (“Green Thumb” or the “Company”) is a leading national cannabis consumer packaged goods company and retailer headquartered in Chicago, Illinois. The company manufactures and distributes a portfolio of branded cannabis products, some of which are licensed, including RYTHM, Dogwalkers, incredibles, Beboe, &Shine, Doctor Solomon’s, and Good Green. Green Thumb also owns and operates RISE Dispensaries, a rapidly growing national retail chain with over 110 locations. Green Thumb serves millions of patients and customers each year with a mission to promote well-being through the power of cannabis while giving back to the communities it serves. Established in 2014, Green Thumb has manufacturing facilities and retail stores across 14 U.S. markets, employing approximately 4,900 people. More information is available at www.gtigrows.com.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements that we believe are, or may be considered to be, “forward-looking statements.” All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “may,” “will,” “expect,” “intend,” “estimate,” “foresee,” “opportunity,” “project,” “potential,” “risk,” “anticipate,” “believe,” “plan,” “forecast,” “continue,” “suggests” or “could” or the negative of these terms or variations of them or similar terms or expressions of similar meaning. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (the “SEC”), or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. These known and unknown risks include, without limitation: cannabis remains illegal under U.S. federal law, and enforcement of cannabis laws could change; future state regulation of cannabis is uncertain; the Company may not be able to obtain or maintain necessary permits and authorizations; the Company may face limitations on ownership of cannabis licenses; the Company may become subject to U.S. Food and Drug Administration or the U.S. Bureau of Alcohol, Tobacco, Firearms, and Explosives regulation; as a cannabis business, the Company is subject to applicable anti-money laundering laws and regulations and have restricted access to banking and other financial services; the Company may face difficulties acquiring additional financing; the Company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where it conducts business; the Company faces intense competition; the Company faces competition from the illicit market as well as hemp products that are actually or purportedly compliant with the Agricultural Improvement Act of 2018 (the Farm Bill); the Company is dependent upon the popularity and consumer acceptance of its brand portfolio that the Company licenses from a third party; the Company has limited trademark protections; as a cannabis business, the Company is subject to unfavorable tax treatment and may incur significant tax liability; as a cannabis business, the Company may be subject to civil asset forfeiture; the Company is subject to proceeds of crime statutes; the Company faces exposure to fraudulent or illegal activity; the Company faces risks due to industry immaturity or limited comparable, competitive or established industry best practices; the Company faces risks related to its products; the Company’s business is subject to the risks inherent in agricultural operations; the Company faces an inherent risk of product liability and similar claims; the Company’s products may be subject to product recalls; the Company may face unfavorable publicity or consumer perception; the Company may be adversely impacted by rising or volatile energy costs and availability; the Company faces risks related to its information technology systems and potential cyber-attacks and security breaches; the Company relies on third-party software providers for numerous capabilities we depend upon to operate, and a disruption of one or more of these systems could adversely affect our business; the Company relies on the expertise of its management team and other employees experienced in the cannabis industry, and the loss of key personnel could negatively affect its business; the Company’s voting control is concentrated; the Company’s capital structure and voting control may cause unpredictability; and sales of substantial amounts Subordinate Voting Shares by the Company’s shareholders in the public market may have an adverse effect on the market price of the Company’s Subordinate Voting Shares. Further information on these and other potential factors that could affect the Company’s business and financial condition and the results of operations are included in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and elsewhere in the Company’s filings with the SEC, which are available (or will become available) on the SEC’s website, and on the Company’s SEDAR+ profile at www.sedarplus.ca, and at https://investors.gtigrows.com. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this document.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Investor Contacts:
Green Thumb Industries Inc.
Page 5 of 7
Mathew Faulkner
Chief Financial Officer
InvestorRelations@gtigrows.com
310-622-8257
Andy Grossman
EVP, Capital Markets & Investor Relations
InvestorRelations@gtigrows.com
888-406-1143
Media Contact:
GTI Communications
media@gtigrows.com
Source: Green Thumb Industries Inc.
Green Thumb Industries Inc.
Page 6 of 7
Highlights from Unaudited Interim Condensed Consolidated Statements of Operations
For the Three Months Ended March 31, 2026 and 2025
(Amounts Expressed in Thousands of United States Dollars, Except for Share Amounts)
|
|
Three Months Ended |
|
||
|
|
March 31, 2026 |
|
March 31, 2025 |
|
|
|
(Unaudited) |
|
(Unaudited) |
|
|
|
|
|
|
|
Revenues, Net of Discounts |
|
$300,190 |
|
$279,540 |
|
Cost of Goods Sold |
|
(156,545) |
|
(136,265) |
|
|
|
|
|
|
|
Gross Profit |
|
143,645 |
|
143,275 |
|
|
|
|
|
|
|
Expenses: |
|
|
|
|
|
Total Expenses |
|
102,911 |
|
100,793 |
|
|
|
|
|
|
|
Income From Operations |
|
40,734 |
|
42,482 |
|
|
|
|
|
|
|
Other Income (Expense): |
|
|
|
|
|
Other Income (Expense), Net |
|
22,967 |
|
(24) |
|
Interest Income |
|
4,603 |
|
2,123 |
|
Interest Expense, Net |
|
(5,165) |
|
(4,865) |
|
|
|
|
|
|
|
Total Other Income (Expense) |
|
22,405 |
|
(2,766) |
|
|
|
|
|
|
|
Income Before Provision for Income Taxes And Non-Controlling Interest |
63,139 |
|
39,716 |
|
|
|
|
|
|
|
|
Provision For Income Taxes |
|
48,092 |
|
31,315 |
|
|
|
|
|
|
|
Net Income Before Non-Controlling Interest |
|
15,047 |
|
8,401 |
|
|
|
|
|
|
|
Net (Loss) Income Attributable To Non-Controlling Interest |
|
(350) |
|
95 |
|
|
|
|
|
|
|
Net Income Attributable To Green Thumb Industries Inc. |
$15,397 |
|
$8,306 |
|
|
|
|
|
|
|
|
Net Income Per Share - Basic |
|
$0.07 |
|
$0.04 |
|
|
|
|
|
|
|
Net Income Per Share - Diluted |
|
$0.07 |
|
$0.04 |
|
|
|
|
|
|
|
Weighted Average Number of Shares Outstanding - Basic |
|
230,596,682 |
|
236,120,511 |
|
|
|
|
|
|
|
Weighted Average Number of Shares Outstanding - Diluted |
|
231,827,061 |
|
236,822,468 |
|
Green Thumb Industries Inc.
Page 7 of 7
Green Thumb Industries Inc.
Highlights from the Unaudited Interim Condensed Consolidated Balance Sheet
(Amounts Expressed in Thousands of United States Dollars)
|
|
|
|
March 31, |
|
|
|
|
2026 |
|
|
|
|
(Unaudited) |
Cash and Cash Equivalents |
|
|
|
$344,512 |
Other Current Assets |
|
|
|
329,338 |
Property and Equipment, Net |
|
|
|
686,499 |
Right of Use Assets, Net |
|
|
|
237,728 |
Intangible Assets, Net |
|
|
|
424,108 |
Goodwill |
|
|
|
591,764 |
Other Long-term Assets |
|
|
|
217,657 |
Total Assets |
|
|
|
$2,831,606 |
Total Current Liabilities |
|
|
|
$194,155 |
Notes Payable, Net of Current Portion and Debt Discount |
|
|
|
266,344 |
Lease Liabilities, Net of Current Portion |
|
|
|
253,463 |
Other Long-Term Liabilities |
|
|
|
220,595 |
Total Equity |
|
|
|
1,897,049 |
Total Liabilities and Equity |
|
|
|
$2,831,606 |
Green Thumb Industries Inc.
Page 8 of 7
Green Thumb Industries Inc.
Supplemental Information (Unaudited) Regarding Non-GAAP Financial Measures
For the Three Months Ended March 31, 2026 and 2025
(Amounts Expressed in Thousands of United States Dollars)
EBITDA, and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under GAAP. We define each term as follows:
(1) EBITDA is defined as earnings before interest, taxes, other income or expense and depreciation and amortization.
(2) Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating (income) or costs.
(3) Normalized EBITDA is defined as Adjusted EBITDA plus brand license fees.
The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.
|
|
Three Months Ended |
||
|
|
March 31, 2026 |
|
March 31, 2025 |
|
|
(Unaudited) |
|
(Unaudited) |
Net Income Before Noncontrolling Interest (GAAP) |
|
$15,047 |
|
$8,401 |
Interest Income |
|
(4,603) |
|
(2,123) |
Interest Expense, Net |
|
5,165 |
|
4,865 |
Provision for Income Taxes |
|
48,092 |
|
31,315 |
Other (Income) Expense, net |
|
(22,967) |
|
24 |
Depreciation and Amortization |
|
32,413 |
|
29,411 |
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (non-GAAP measure) |
|
$73,147 |
|
$71,893 |
Share-based Compensation, Non-Cash |
|
10,517 |
|
10,309 |
Acquisition, Transaction, and Other Non-Operating (Income) Costs |
|
870 |
|
3,045 |
Adjusted EBITDA (non-GAAP measure) |
|
$84,534 |
|
$85,247 |
|
|
|
|
|
License Fee recorded in Cost of Sales |
|
8,978 |
|
— |
Normalized EBITDA (Non-GAAP Measure) |
|
$93,512 |
|
$85,247 |